<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04879485</url>
  </required_header>
  <id_info>
    <org_study_id>1-10-72-289-20</org_study_id>
    <nct_id>NCT04879485</nct_id>
  </id_info>
  <brief_title>Prehospital Transfusion Strategy in Bleeding Patients</brief_title>
  <official_title>Prehospital Plasma or Red Blood Cell Transfusion Strategy in Major Bleeding; PRIEST Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norwegian Air Ambulance Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Copenhagen University Hospital, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of study is to compare clinical and biochemical effect of three different transfusion&#xD;
      strategies among patients with major hemorrhage requiring prehospital transfusion.&#xD;
&#xD;
      A) Present prehospital standard treatment including a mixture of plasma and Red blood cell&#xD;
      transfusion (RBC) transfusion B) Red blood cell transfusion (RBC) only C) Plasma transfusion&#xD;
      only&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
        1. Transfusion strategy including a mixture of RBC and plasma is superior as compared with&#xD;
           only plasma or only RBC strategy in terms of initial treatment of circulatory shock&#xD;
           (expressed as base deficit).&#xD;
&#xD;
        2. Endothelial function and ability of clot formation is preserved to a greater extent in&#xD;
           patients receiving plasma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale for the study:&#xD;
&#xD;
      The warranted clinical question to be unsolved is whether initial pre-hospital transfusion in&#xD;
      bleeding patients should base on a strategy including plasma, RBC or combination of both.&#xD;
&#xD;
      Despite possible benefits, allogenic blood product are associated with side effects and pose&#xD;
      significant logistic challenges in the prehospital environment. So far, a majority of the&#xD;
      present knowledge is based on retrospective evaluations or clinical trials without relevant&#xD;
      control groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Base deficit</measure>
    <time_frame>At hospital arrival (with in 1 hour)</time_frame>
    <description>Arterial-gas analysis upon arrival with parameter base deficit as primary outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>30 days mortality</measure>
    <time_frame>mortality within 30 days</time_frame>
    <description>Mortality, follow up in patient records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activated Partial Thromboplastin Time (APTT)</measure>
    <time_frame>At hospital arrival (with in 2 hours)</time_frame>
    <description>Plasma sample analysed; APTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endogenous thrombin potential (ETP)</measure>
    <time_frame>At hospital arrival (with in 2 hours)</time_frame>
    <description>Plasma sample analysed; thrombin generation assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Normalized Ratio (INR)</measure>
    <time_frame>At hospital arrival (with in 2 hours)</time_frame>
    <description>Plasma sample analysed; INR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelium markers</measure>
    <time_frame>At hospital arrival (with in 2 hours)</time_frame>
    <description>Plasma sample analysed; Syndecan-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelium markers</measure>
    <time_frame>At hospital arrival (with in 2 hours)</time_frame>
    <description>Plasma sample analysed; soluble thrombomodulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In hospital red blood cell transfusion requirements</measure>
    <time_frame>Within in the first 24 hours after hospital arrival</time_frame>
    <description>Amount of red blood cells transfused as registered in patient electronic records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In hospital plasma transfusion requirements</measure>
    <time_frame>Within in the first 24 hours after hospital arrival</time_frame>
    <description>Amount of plasma transfused as registered in patient electronic records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In hospital platelet transfusion requirements</measure>
    <time_frame>Within in the first 24 hours after hospital arrival</time_frame>
    <description>Amount of platelet transfused as registered in patient electronic records</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hemorrhage</condition>
  <condition>Blood Component Transfusion</condition>
  <arm_group>
    <arm_group_label>Standard transfusion</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Includes standard transfusion with a mixture of red blood cells and plasma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plasma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transfusion with plasma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Red Blood cells</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transfusion with red blood cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood products</intervention_name>
    <description>Compare two different transfusion strategies against standard transfusion regimen</description>
    <arm_group_label>Plasma</arm_group_label>
    <arm_group_label>Red Blood cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Major bleeding requiring prehospital transfusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Transfusion with blood products already initiated&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Fenger-Eriksen</last_name>
    <role>Study Chair</role>
    <affiliation>Aarhus Universityhospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Fenger-Eriksen, PhD</last_name>
    <phone>+45 7846 6912</phone>
    <email>christian.fenger-eriksen@viborg.rm.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aarhus Universityhospital</name>
      <address>
        <city>Silkeborg</city>
        <state>Midtjylland</state>
        <zip>8600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Fenger-Eriksen</last_name>
      <phone>26362416</phone>
      <email>christian.fenger-eriksen@viborg.rm.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Danish Air Ambulance</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Fenger-Eriksen</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

